Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors
© Si-Tayeb et al; licensee BioMed Central Ltd. 2010
Received: 7 May 2010
Accepted: 3 August 2010
Published: 3 August 2010
The use of lentiviruses to reprogram human somatic cells into induced pluripotent stem (iPS) cells could limit their therapeutic usefulness due to the integration of viral DNA sequences into the genome of the recipient cell. Recent work has demonstrated that human iPS cells can be generated using episomal plasmids, excisable transposons, adeno or sendai viruses, mRNA, or recombinant proteins. While these approaches offer an advance, the protocols have some drawbacks. Commonly the procedures require either subcloning to identify human iPS cells that are free of exogenous DNA, a knowledge of virology and safe handling procedures, or a detailed understanding of protein biochemistry.
Here we report a simple approach that facilitates the reprogramming of human somatic cells using standard techniques to transfect expression plasmids that encode OCT4, NANOG, SOX2, and LIN28 without the need for episomal stability or selection. The resulting human iPS cells are free of DNA integration, express pluripotent markers, and form teratomas in immunodeficient animals. These iPS cells were also able to undergo directed differentiation into hepatocyte-like and cardiac myocyte-like cells in culture.
Simple transient transfection of plasmid DNA encoding reprogramming factors is sufficient to generate human iPS cells from primary fibroblasts that are free of exogenous DNA integrations. This approach is highly accessible and could expand the use of iPS cells in the study of human disease and development.
Human iPS cells are potentially valuable tools for the study of human development and disease. If human iPS cells are generated from specific patients they offer an opportunity to study the molecular mechanism underlying the pathogenesis [1, 2]. Because human iPS cells can be derived from a patient's own cells they may ultimately provide the means for effective cell therapy, avoiding concerns associated with immune rejection. However, before iPS cell-based therapeutics can be realized, it is important that a reliable, reproducible, accessible, and safe reprogramming protocol is adopted.
Current human iPS production techniques have several limitations that restrict their clinical usefulness. For example, most reprogramming procedures result in clones of iPS cells in which the extent of reprogramming can be heterogeneous. The derivation of fully reprogrammed iPS cells, therefore, requires fastidious attention to detail with laborious, time-consuming production and screening procedures. Recent studies have suggested that the inclusion of Valproic Acid or Sodium Butyrate may enhance complete reprogramming [3, 4].
In addition to the heterogeneity associated with reprogramming, the most commonly used reprogramming protocols use lentiviruses, which integrate into the host cell's genome and are potentially mutagenic. The choice of using lentiviruses to reprogram is partly historical. Initial studies showed that the use of lentiviruses to transduce exogenous factors (OCT4, SOX2, NANOG and LIN28 or OCT3/4, SOX2, KLF4 and C-MYC) into genomic DNA was sufficient to reprogram human somatic cells [5, 6]. Since expression of the viral cDNAs was repressed by methylation this allows transient expression of reprogramming factors until endogenous regulators of pluripotency take over. The transient expression of reprogramming factors may be important because even subtle changes in expression of these genes can induce cell differentiation . Studies using mouse cells have shown that expression of the exogenous reprogramming factors is required for a minimum of 12 days to produce iPS cells . Although the need for extended expression of introduced cDNAs suggested that the use of non-integrating approaches would be challenging, Stadtfeld et al. demonstrated that genomic integration was not essential to successfully reprogram mouse fibroblasts, by using adenoviruses to supply cDNAs encoding reprogramming factors .
Recently, a number of publications [10, 11] have reported the production of human iPS cells that are free of transgenic sequences using a variety of strategies including infection of cells with recombinant adenoviruses and sendai viruses. Although the use of these viruses circumvent genomic integration of DNA, they require a knowledge of virology to produce high titer viruses and adherence to increasingly strict biosafety regulations. Kim et al  were able to generate human iPS cells by directly delivering reprogramming proteins (OCT4, SOX2, KLF4 and C-MYC). The reprogramming proteins were fused to a peptide highly enriched in basic amino acids, which allowed them to cross the cell membrane barrier. The cells were then seeded on mouse feeder cells, and human iPS-like colonies were picked 56 days after first exposure to the reprogramming proteins. This protocol was advantageous as it did not directly use genetic material to reprogram the somatic cells. However, one limitation was that a cell extract of stably transfected HEK-293T cells had to be added once a week for six weeks.
A number of reports have shown that nucleic acids that do not integrate into the recipient genome can be used successfully to make iPS cells. Yu et al  demonstrated that human iPS cells could be generated from a single nucleofection of three oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based episomal vectors coding for seven factors (OCT4, SOX2, NANOG, LIN28, KLF4, C-MYC, and SV40Tag), after drug selection and seeding on mouse feeder cells. However, although the presence of oriP/EBNA1 ensured maintenance of the plasmids even after reprogramming, all human iPS cells generated by this approach therefore had to be subcloned to isolate human iPS cell lines void of vector DNA.
While all of these techniques could be valuable, they all suffer from a lack of simplicity and in some cases require substantial knowledge of virology or protein biochemistry. We reasoned that an ideal reprogramming approach would rely on the use of elementary procedures that were readily accessible to any lab with even rudimentary experience in molecular biology. Since Yu and colleagues  had successfully used nucleofection with episomal vectors, we addressed whether simple transient transfection of plasmid DNA could generate human iPS cells. We show that two sequential transfections of non-episomal plasmids that independently encode four reprogramming factors (OCT4, NANOG, SOX2 and LIN28) are sufficient to generate human iPS cells. In addition to exhibiting pluripotent cell features, the resulting integration-free human iPS cells have the ability to generate hepatocyte-like cells and cardiac myocytes following directed differentiation in culture.
Generation of integration-free virus-free human induced pluripotent stem cells
At the end of the reprogramming protocol, alkaline phosphatase activity was evaluated (Figure 1B). Compared to the lentivirus-based reprogramming protocol, plasmid transfection led to a similar number of colonies displaying alkaline phosphatase activity. However, even though alkaline phosphatase activity is considered to be a marker of pluripotency in embryonic stem cells , it is detected early in the reprogramming process and does not necessarily reflect a fully reprogrammed state .
The absence of plasmid DNA was confirmed by performing genomic PCR using primers that specifically amplify puromycin N-acetyl-transferase sequence (Figure 3B). An amplification product was successfully detected when DNA from control lentiviral-derived iPSC2 cells was used as a template. In contrast, amplicons were not identified in DNA from control H9 cells or from iPSK3 cells. From these data we conclude that the reprogrammed iPSK3 cells are devoid of plasmid sequences, at least within the resolution offered by the assays.
Differentiation of iPSK3 cells into hepatocyte-like cells
Differentiated cells were then incubated with 5-(and 6)-carboxy-2'-7'-dichlorofluorescein diacetate (DCF-DA). DCF-DA is membrane permeable and becomes trapped inside the cells after cleavage by intracellular esterase into DCF and DA. DCF, however, can be secreted between hepatocyte-like cells via bile canaliculi through specific transporters . Hepatocyte-like cells derived from iPSK3 efficiently secreted the fluorescent compound, demonstrating the presence of functional bile transporters (Figure 4B; see inset, white arrow). Finally, the differentiated cells also expressed several hepatic markers including FoxA2, E-cadherin, HNF4α, α-fetoprotein, and Albumin (Figure 4C). Overall, our data suggest that the iPSK3 were competent to form hepatocyte-like cells.
Directed differentiation of human iPSK3 cells into cardiac myocytes
Additional file 1: Beating cluster of cardiac myocytes derived from iPSK3 cells. (AVI 11 MB)
Cytosolic calcium transients were monitored using the fluo-4 AM fluorescent indicator, which is calcium sensitive. Figure 5B shows a montage of rhythmic oscillation of intracellular calcium waves based on video acquisition (Additional file 2). Analysis of intracellular calcium released from individual cells among the beating network (Figure 5C, upper) showed a heterogeneous population consisting of atrial-like cardiac myocytes (Figure 5C, lower left) that displayed a higher frequency of intracellular calcium oscillation and shorter periodicity, along with ventricular-like cardiac myocytes (Figure 5C, lower right), with a lower frequency of intracellular oscillation and longer periods. These data confirm that iPSK3 cells can be induced to differentiate into distinct populations of functional cardiac myocytes in culture.
In this report, we describe the generation of human iPS cells devoid of exogenous DNA by the simple transient transfection of plasmids that express reprogramming factors. These newly reprogrammed somatic cells display pluripotent markers and were found to form teratomas in immunodeficient mice that were composed of all three germ layers. In addition, our data demonstrate that the iPSK3 cells produced by this process could form hepatocyte-like cells and contracting cardiac myocytes upon directed differentiation in culture.
Despite the observation that similar numbers of colonies expressing alkaline phosphatase activity were identified between lentiviral transduction and plasmid transfection, the use of plasmids is less efficient for full reprogramming of somatic cells. Based on the successful isolation of a single fully reprogrammed colony, the efficiency of human iPS cell reprogramming by plasmid transfection (1 iPS cell from 300,000 fibroblasts) was similar to that reported for the use of adenovirus (0.0002%) , which is approximately ten-fold lower (0.01%) when reprogramming is performed with lentiviruses . This lower efficiency presumably reflects a reduction in sustainable expression of the reprogramming factors because the presence of plasmid DNA within the cells is transient. A substantial effort by multiple labs has resulted in the description of small molecules that can enhance the efficiency of reprogramming (See review by Li and Ding ). For example increases up to 200-fold in reprogramming efficiency have been reported by including antagonists of TGFbeta signaling in addition to MEK-ERK inhibitors and passaging the cells in the presence of Thiazovivin . In addition, inclusion of Valproic Acid or Sodium Butyrate may enhance complete reprogramming [3, 4]. It therefore seems likely that such drug combinations could be used to increase the efficiency of reprogramming by transient transfection of expression plasmids.
The main advantage of the current approach is that it allows direct reprogramming of human somatic cells into human iPS cells devoid of exogenous DNA without the need for extensive experimental procedures [12, 13]. While several other procedures have been described for producing iPS cells free of integrating DNA, most require some level of specialized knowledge of virology or biochemistry. Although the frequency of recovering completely reprogrammed iPS cells is lower than using lentiviral transduction, the simplicity and accessibility of using transient transfection should also compensate for the reduced efficiency.
In conclusion, we have shown that simple transient transfection of plasmid DNA encoding reprogramming factors is sufficient to generate human iPS cells from primary fibroblasts that are free of exogenous DNA integrations. This approach is simple, highly accessible and could expand the use of iPS cells in the study of human disease and development, as well as increase the availability of safer iPS cells for potentially therapeutic uses.
Human iPS cells were cultured on mitotically inactivated mouse embryonic fibroblasts (MEFs) in a stem cell medium composed of Dulbecco's modified Eagle's medium/Ham's F-12 (DMEM/F12) supplemented with 20% knockout serum (Invitrogen, Carlsbad, CA), non-essential amino acids solution (Invitrogen, Carlsbad, CA), glutamine (Invitrogen, Carlsbad, CA), penicillin/streptomycin (Invitrogen, Carlsbad, CA) and bFGF (4 ng/ml; Invitrogen, Carlsbad, CA) and maintained under low oxygen conditions (4% O2; 5% CO2) for 7 days. Cells were manually passaged once a week on MEFs, by using Accutase (Millipore, Billerica, MA) on Matrigel, or on a recombinant protein substrate (StemAdhere™, Primorigen Inc, Madison, WI) as described previously . For differentiation experiments, MEF-conditioned medium was used to maintain pluripotency while transferring the cells onto feeder cell-free Matrigel-coated plates. All work carried out using human iPS cells was approved by the MCW Human Stem Cell Research Oversight Committee (hSCRO approval# 09-005) committee and all work performed using animals was approved by the MCW IACUC.
On day 0, 1 × 105 human foreskin fibroblasts (ATCC cell line CRL2097) were plated on an uncoated 100 mm dish. To introduce DNA, pSin vectors coding for OCT4, NANOG, SOX2, and LIN28  were mixed with Fugene 6 (Roche Applied Science, Indianapolis, IN) in a 2:1 ratio of Fugene:DNA and transfections were performed on day 1 and 8 of reprogramming. Stem cell medium was used for all cell culture starting on day 2 of reprogramming, and the MEK1 inhibitor PD0325901 (StemGent, Cambridge, MA) was added to the medium on day 15 at a final concentration of 1 μM. The medium was changed daily. After four to five weeks, emerging colonies were manually collected and plated on mitotically-inactivated MEFs for subsequent characterization. Lentivirus-based reprogramming utilized the same culture conditions as described above; however, the cells were infected with concentrated replication-incompetent pseudotyped lentiviruses that express OCT4, NANOG, SOX2 and LIN28.
Alkaline Phosphatase activity
Pluripotent cells in culture on MEFs were fixed with 4% paraformaldehyde for 2 min at room temperature. The cells were then rinsed with TBST (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.05% Tween-20) and incubated for 15 min at room temperature with a mixture of Fast Red Violet, Naphtol AS-BI phosphate solution and water (2:1:1) from the Alkaline Phosphatase Detection Kit (Millipore, Billerica, MA) according to the manufacturer's protocol. Following staining, the cells were rinsed with TBST and covered with phosphate-buffered saline (PBS).
Karyotyping and DNA fingerprinting
Karyotyping and DNA fingerprinting of the human induced pluripotent cell lines was performed by Cell Line Genetics, Madison, WI (http://www.clgenetics.com/).
Human iPS cell line, iPSK3, was cultured on MEFs with one dense 60 mm plate used per assay. Cells were manually removed using the StemPro EZPassage tool (Invitrogen), collected by centrifugation and resuspended in 250 μl of Matrigel (2 mg/ml in DMEM-F12; BD Bioscience). Approximatively 2 × 106 cells were then injected into the posterior dorsal side of immunodeficient Rag2-/-; Il2rg-/- mice using a 27G needle. Resulting teratomas were dissected 8 to 9 weeks after injection, fixed overnight with Zinc-formalin and embedded in paraffin before 4 μm sections were stained with hematoxilin and eosin. All animal procedures were approved by the MCW IACUC.
Cultured cells were fixed with 4% paraformaldehyde for 30 min at room temperature, permeabilized with 0.5% Triton X-100 in PBS for 15 min and blocked with 3% BSA in PBS for 15 min. Cells were incubated overnight at 4°C with primary antibodies diluted in 1% BSA in PBS (Oct3/4 1:500; SSEA4 1:100; GATA4 1:500; Cardiac Troponin T 1:100; FoxA2 1:250; Hnf4a 1:500; E-cadherin 1:1000; alpha-fetoprotein 1:500; Albumin 1:500). After incubation with respective secondary antibodies (Alexa Fluor 488 or 568; Invitrogen, Carlsbad, CA) for 1 h at room temperature, cell nuclei were identified using DAPI and samples were mounted using ProLong Gold Antifade Mounting Reagent (Invitrogen, Carlsbad, CA).
Flow Cytometry analysis
Cultured cells were dissociated using a PBS-based Cell Dissociation Buffer (Invitrogen), washed with 0.25% BSA in PBS and stained 1 hour with antibodies directed against CD13-Alexa 488 nm, OCT3/4-PerCP, SSEA4-Alexa 488 nm, TRA1-60-PE or TRA1-81-PE (CD13 1 μg; Oct3/4 1 μg; SSEA4 0.5 μg; TRA1-60 1 μg; TRA1-81 1 μg) at 4°C. Flow cytometry analysis was performed using the Guava EasyCyte Minisystem (Millipore, Billerica, MA).
Southern blot and PCR analysis
The cells were incubated overnight with a cell lysis buffer (4 M urea, 10 mM CDTA, 0.5% sarkosyl, 0.1 M Tris-HCL, pH 8.0, 0.2 M NaCl) and 1 mg/ml proteinase K at 55°C. The next day, isopropanol was added and the DNA was spooled out and dissolved in 10 mM Tris-HCL, pH 8.0, 0.1 mM EDTA. Genomic DNA was digested with BamHI and resolved on a 0.7% agarose gel at 23 V overnight. After denaturing, DNA from the gel was transferred to a Zetaprobe GT membrane (Bio-Rad, Hercules, CA). Fragments were amplified by PCR to generate a radioactively-labeled probe that recognized puromycin N-acetyl-transferase (which confers resistance against puromycin in eukaryotic cells) or FOXD3 as a control for all DNA samples. PCR analysis was performed on 2 ng of DNA using specific primers for puromycin N-acetyl-transferase (Puro) and human Alu repeat as a loading control. Primers used to generate probes and amplicons: Puro, GTCACCGAGCTGCAAGAACT and GTCCTTCGGGCACTCGAC; FOXD3, GTGAAGCCGCCTTACTCGTAC and CCGAAGCTCTGCATCATGAG; Alu, AATATGGCCCAACTGCAGAA and CATCGCATTTTCACATCCAA.
Hepatocyte-like cell differentiation
Pluripotent cells were differentiated using the method described previously . To assess cell polarity hepatocyte-like cells were incubated for 10 min with 5-(and 6)-carboxy-2'-7'-dichlorofluorescein diacetate (DCF-DA; Biotium) at a final concentration of 2 μg/ml. Cells were then washed three times with hepatocyte culture medium and immediately observed under a fluorescent microscope.
Cardiac myocyte differentiation
Pluripotent cells were manually dissected from MEFs and plated on 6-well plates pre-coated with Matrigel and kept under 4% O2/5% CO2 at 37°C for 1 week. To induce cardiac differentiation, cells were incubated for 5 days in RPMI/B27 medium (Invitrogen, Carlsbad, CA), supplemented with 50 ng/ml human recombinant Activin A (R & D systems, Minneapolis, MN) and 10 ng/ml BMP4 (Peprotech, Inc, Rocky Hill, NJ) in a 4% O2/5% CO2 atmosphere. After 5 days, treated cells were then placed in a 5% CO2 and ambient oxygen atmosphere, and the RPMI/B27 medium was changed every 2 days. Clusters of beating cells were observed 15-20 days after starting the differentiation process.
Intracellular calcium measurements
Intracellular calcium transients in human iPS cell-derived cardiac myocytes were measured using fluo-4 AM fluorescent indicator (Invitrogen, Carlsbad, CA) in RPMI/B27 medium. Fluo-4 AM (2 μM) was loaded for 20 min at 37°C, followed by a 5 min dye washout. Rhythmically contracting areas were visualized using a laser-scanning confocal microscope (Eclipse TE2000-U; Nikon, Tokyo, Japan) with a Plan Apo 10× air NA 0.45 objective lens (Nikon Corp, Tokyo). Images were acquired every 700 ms using EZ-C1 software (EZ-C1 2.10, Nikon Corp, Tokyo), and data were analyzed with MetaMorph 6.1 software (Universal Imaging, West Chester, PA).
The authors thank Karen Vieira for editing the manuscript. Work was supported by gifts from the Marcus Family, Phoebe R and John D Lewis Foundation, the Sophia Wolf Quadracci Memorial Fund, and the Dr James Guhl Memorial Fund as well as NIH grants HL034708 (ZJB), DK55743, DK087377 (SAD), and HL089471 (SAD, JWL).
- Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R: Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009, 136: 964-977. 10.1016/j.cell.2009.02.013.PubMed CentralView ArticlePubMedGoogle Scholar
- Ebert AD, Yu J, Rose FFJ, Mattis VB, Lorson CL, Thomson JA, Svendsen CN: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009, 457: 277-280. 10.1038/nature07677.PubMed CentralView ArticlePubMedGoogle Scholar
- Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008, 26: 1269-1275. 10.1038/nbt.1502.View ArticlePubMedGoogle Scholar
- Mali P, Chou BK, Yen J, Ye Z, Zou J, Dowey S, Brodsky RA, Ohm JE, Yu W, Baylin SB, Yusa K, Bradley A, Meyers DJ, Mukherjee C, Cole PA, Cheng L: Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency-Associated Genes. Stem Cells. 2010Google Scholar
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019.View ArticlePubMedGoogle Scholar
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007, 318: 1917-1920. 10.1126/science.1151526.View ArticlePubMedGoogle Scholar
- Rizzino A: Sox2 and Oct-3/4: A Versatile Pair of Master Regulators that Orchestrate the Self-renewal and Pluripotency of Embryonic Stem Cells by Functioning as Molecular Rheostats. Wiley Interdiscip Rev Syst Biol Med. 2009, 1: 228-236. 10.1002/wsbm.12.PubMed CentralView ArticlePubMedGoogle Scholar
- Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H, Jaenisch R: Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell. 2008, 2: 151-159. 10.1016/j.stem.2008.01.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science. 2008, 322: 945-949. 10.1126/science.1162494.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou W, Freed CR: Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 2009, 27: 2667-2674. 10.1002/stem.201.View ArticlePubMedGoogle Scholar
- Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M: Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009, 85: 348-362. 10.2183/pjab.85.348.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS: Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009, 4: 472-476. 10.1016/j.stem.2009.05.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA: Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009, 324: 797-801. 10.1126/science.1172482.PubMed CentralView ArticlePubMedGoogle Scholar
- Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA: Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010, 51: 297-305. 10.1002/hep.23354.PubMed CentralView ArticlePubMedGoogle Scholar
- O'Connor MD, Kardel MD, Iosfina I, Youssef D, Lu M, Li MM, Vercauteren S, Nagy A, Eaves CJ: Alkaline phosphatase-positive colony formation is a sensitive, specific, and quantitative indicator of undifferentiated human embryonic stem cells. Stem Cells. 2008, 26: 1109-1116. 10.1634/stemcells.2007-0801.View ArticlePubMedGoogle Scholar
- Khetani SR, Bhatia SN: Microscale culture of human liver cells for drug development. Nat Biotechnol. 2008, 26: 120-126. 10.1038/nbt1361.View ArticlePubMedGoogle Scholar
- Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM: Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008, 453: 524-528. 10.1038/nature06894.View ArticlePubMedGoogle Scholar
- Yao S, Chen S, Clark J, Hao E, Beattie GM, Hayek A, Ding S: Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci USA. 2006, 103: 6907-6912. 10.1073/pnas.0602280103.PubMed CentralView ArticlePubMedGoogle Scholar
- Li W, Ding S: Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol Sci. 2010, 31: 36-45. 10.1016/j.tips.2009.10.002.View ArticlePubMedGoogle Scholar
- Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, Lin X, Hahm HS, Hao E, Hayek A, Ding S: A chemical platform for improved induction of human iPSCs. Nat Methods. 2009, 6: 805-808. 10.1038/nmeth.1393.PubMed CentralView ArticlePubMedGoogle Scholar
- Nagaoka M, Si-Tayeb K, Akaike T, Duncan SA: Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratum. BMC Dev Biol. 2010, 10: 60-10.1186/1471-213X-10-60.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.